A systematic overview of chemotherapy effects in ovarian cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Acta oncologica

• Publication date

  2001-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/02841860151116420PMID 11441940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer

  2004cited by this paper
• Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy

  2004cited by this paper
• Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma

  2004cited by this paper
• Prediction of cancer incidence in the Nordic countries up to the year 2020.

  2002cited by this paper
• Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG).

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.

  2000cited by this paper
• Long term survival analysis of high dose versus low dose cis-platinum combined with cyclophosphamide in advanced ovarian cancer

  1999cited by this paper
• Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.

  1999cited by this paper
• Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993

  1998cited by this paper
• Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975‐94 and treated at the Norwegian Radium Hospital

  1998cited by this paper
• Prognostic factors in ovarian cancer.

  1998cited by this paper
• Carboplatin versus cisplatin in solid tumors: an analysis of the literature.

  1998cited by this paper
• Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.

  1998cited by this paper
• Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  1998cited by this paper
• Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.

  1998cited by this paper
• Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

  1998cited by this paper
• Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

  1998cited by this paper
• Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

  1998cited by this paper
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.

  1998cited by this paper
• Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

  1997cited by this paper
• A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study.

  1997cited by this paper
• Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

  1997cited by this paper
• Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.

  1997cited by this paper
• Prognostic factors in salvage therapy of ovarian cancer.

  1997cited by this paper
• Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.

  1997cited by this paper
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

  1997cited by this paper
• Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.

  1997cited by this paper
• Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

  1997cited by this paper
• Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].

  1997cited by this paper
• Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.

  1997cited by this paper
• Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide.

  1997cited by this paper
• Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.

  1997cited by this paper
• [Better prognosis in epithelial ovarian cancer].

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Topotecan in platinum- and paclitaxel-resistant ovarian cancer.

  1997cited by this paper
• The epidemiology of epithelial ovarian cancer: a review

  1997cited by this paper
• Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

  1996cited by this paper
• Natural history and prognosis of untreated stage I epithelial ovarian carcinoma.

  1996cited by this paper
• -Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-.

  1996cited by this paper
• Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

  1996cited by this paper
• Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

  1996cited by this paper
• Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs

  1996cited by this paper
• Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.

  1996cited by this paper
• Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.

  1996cited by this paper
• High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

  1996cited by this paper
• Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.

  1996cited by this paper
• Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

  1996cited by this paper
• Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

  1996cited by this paper
• Randomized trial of initial therapy with melphalan versus cisplatin‐based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878

  1996cited by this paper
• Paclitaxel (Taxol * ) as Salvage Therapy for Relapsed Ovarian Cancer

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

  1995cited by this paper
• Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

  1995cited by this paper
• Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)

  1995cited by this paper
• The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

  1995cited by this paper
• Impact of doxorubicin on survival in advanced ovarian cancer.

  1995cited by this paper
• Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.

  1995cited by this paper
• European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

  1994cited by this paper
• Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

  1994cited by this paper
• Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.

  1994cited by this paper
• Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

  1994cited by this paper
• Tamoxifen in patients with advanced epithelial ovarian cancer

  1994cited by this paper
• Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.

  1994cited by this paper
• Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

  1994cited by this paper
• A population-based survey of ovarian malignancies in the southeast health care region of Sweden 1984-1987.

  1994cited by this paper
• Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

  1994cited by this paper
• Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

  1994cited by this paper
• Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.

  1994cited by this paper
• Paclitaxel (taxol) treatment for refractory ovarian cancer : phase II clinical trial. Discussion

  1994cited by this paper
• Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

  1994cited by this paper
• Hexamethylmelamine as second‐line therapy in platin‐resistant ovarian cancer

  1993cited by this paper
• A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles.

  1993cited by this paper
• The impact of received dose intensity on the outcome of advanced ovarian cancer.

  1993cited by this paper
• Intraperitoneal Chemotherapy of Ovarian Cancer

  1993cited by this paper
• Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.

  1993cited by this paper
• Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

  1993cited by this paper
• Management of Borderline Tumors of the Ovary

  1993cited by this paper
• Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer.

  1993cited by this paper
• Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries.

  1993cited by this paper
• Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.

  1993cited by this paper
• The West Midlands epithelial ovarian cancer adjuvant therapy trial.

  1993cited by this paper
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

  1993cited by this paper
• Response to Taxol chemotherapy in resistant ovarian carcinoma.

  1993cited by this paper
• Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

  1992cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.

  1992cited by this paper
• Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy.

  1992cited by this paper
• Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.

  1992cited by this paper
• CA125 in peritoneal fluid of ovarian cancer patients

  1992cited by this paper
• Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125.

  1992cited by this paper
• Meta-Analysis of Cisplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin and Cyclophosphamide Chemotherapy of Ovarian Carcinoma

  1992cited by this paper
• Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

  1992cited by this paper
• Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging.

  1991cited by this paper
• Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

  1991cited by this paper
• Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

  1991cited by this paper
• Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.

  1991cited by this paper
• Watch and wait after careful surgical treatment and staging in well‐differentiated early ovarian cancer

  1991cited by this paper

• Niraparib-Associated Pulmonary Embolism in a Patient with BRCA Mutant Ovarian Cancer

  2025cites this paper
• Deciphering the transcriptional alterations in high grade serous ovarian cancer upon catalytic inactivation of protein kinase D.

  2025cites this paper
• Deciphering the transcriptional alterations in high grade serous ovarian cancer upon catalytic inactivation of protein kinase D.

  2025cites this paper
• Clinical analysis of the impact of systematic pelvic and para-aortic lymphadenectomy on the prognosis of patients with early-stage ovarian cancer (stage IA–IIA): a propensity score matching study

  2025cites this paper
• Synthesis of 1, 2-Disubstituted Benzimidazoles at Ambient Temperature Catalyzed by 1-Methylimidazolium Tetraflouroborate ([Hmim] BF_4) and Investigating Their Anti-ovarian Cancer Properties Through Molecular Docking Studies and Calculations

  2024cites this paper
• Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer.

  2024cites this paper
• Stage IC grade 1 endometrioid adenocarcinoma of the ovary: assessment of post-operative chemotherapy de-escalation

  2024cites this paper
• Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements

  2023cites this paper
• Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial

  2023cites this paper
• SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway

  2023cites this paper
• Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis

  2022cites this paper
• Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study

  2021cites this paper
• Inhibition of SKOV3 cell proliferation, migration and invasion by arborinine via decreased expression of lysine specific demethylase 1.

  2021cites this paper
• Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

  2021cites this paper
• Inhibition of Proliferation in Ovarian Cancer Cell Line (PA-1) by the Action of Green Compound “Betanin”

  2021cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020

  2021cites this paper
• Caffeine and Cisplatin Effectively Targets the Metabolism of a Triple-Negative Breast Cancer Cell Line Assessed via Phasor-FLIM

  2020cites this paper
• Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research

  2020cites this paper
• Ovarian cancer: Current status and strategies for improving therapeutic outcomes

  2019cites this paper
• Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma

  2019cites this paper
• Ovarian Cancer

  2019cites this paper
• LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis

  2019cites this paper
• Emerging growth factor receptor antagonists for ovarian cancer treatment

  2018cites this paper
• Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker

  2018cites this paper
• The clinical study of secondary cytoreductive surgery in the treatment of low grade serous ovarian cancer

  2017cites this paper
• Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy.

  2017cites this paper
• Novel Chemotherapy Tools

  2017cites this paper
• Therapeutic efficacy of nanomedicines for prostate cancer: An update

  2016cites this paper
• Krukenberg tumors. Prognostic factors, surgical treatment and survival benefit. A literature review

  2016cites this paper
• Clinicopathological , Epidemiologic Characteristics and Treatment Outcomes of Ovarian Cancer Patients at NCI , Cairo University

  2016cites this paper
• Patient-reported Measurements of Oral Mucositis in Pediatric Patients withCancer

  2016cites this paper
• The Role Of Oxidative Stress In The Establishment Of Resistance To Cisplatin In Epithelial Ovarian Cancer Cells

  2016cites this paper
• Biocompatible poly(N-isopropylacrylamide)-g-carboxymethyl chitosan hydrogels as carriers for sustained release of cisplatin

  2015cites this paper
• articleA genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

  2015cites this paper
• The Management of Ovarian Cancer in Bangladesh: A Report of a Long-Term Survivor

  2015cites this paper
• Effects of Paclitaxel and Carboplatin Combination on Mechanical Myocardial and Microvascular Functions: A Transthoracic Doppler Echocardiography and Two‐Dimensional Strain Imaging Study

  2015cites this paper
• cis-Dichlorodiamminoplatinum (II) glyconanoparticles by drug-induced ionic gelation technique targeted to prostate cancer: preparation, optimization and in vitro characterization.

  2014cites this paper
• Immature Citrus Fruit Extracts Enhance the Apoptosis Inducing Potential of Cisplatin in Human Malignant Melanoma A375 Cells via Regulation of Nitric Oxide and Inhibitor of Apoptosis Family (IAP)

  2014cites this paper
• Ocena wybranych markerów nowotworowych u kobiet z rakiem jajnika i innymi chorobami narządu rodnego

  2014cites this paper
• Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways

  2014cites this paper
• The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.

  2014cites this paper
• A rapid and sensitive determination of paclitaxel in rat plasma by UPLC-MS/MS method: Application to a pharmacokinetic study

  2013cites this paper
• SOX2 Expression und die prognostische Bedeutung bei Ovarialkarzinomen

  2013cites this paper
• Targeting the anaphase promoting complex/cyclosome to induce mitotic arrest in ovarian cancer.

  2013cites this paper
• Identification of prognostic factors for Krukenberg tumor

  2013cites this paper
• Intensity modulated radiotherapy in gynecologic cancers: hope, hype or hyperbole?

  2013cites this paper
• Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and Survival Following a Mucinous Epithelial Ovarian Cancer Diagnosis

  2013cites this paper
• 18β-Glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway

  2012cites this paper
• Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population

  2012cites this paper
• Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway

  2012cites this paper
• Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy.

  2012cites this paper
• Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.

  2012influential citation
• Diagnosis and treatment of sarcoma of the uterus. A review

  2012cites this paper
• Effect of platinum-containing chemotherapy on olfactory, gustatory, and hearing function in ovarian cancer patients

  2012cites this paper
• Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.

  2012cites this paper
• Universal Application of Colonoscopy Mitigates Unnecessary Laparotomy in Patients with Pelvic Tumors of Unknown Origin

  2012cites this paper
• Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University

  2012cites this paper
• Hox Gene Expression in Ovarian Cancer

  2012cites this paper
• Effect of Green Tea Extract on Cisplatin-or Doxorubicin-Induced Cytotoxicity in Human Lung Cancer Cell Lines

  2011cites this paper
• Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins

  2011cites this paper
• 8-Hydroxynaphthalene-1,4-dione derivative as novel compound for glioma treatment.

  2011cites this paper
• Cyclophosphamide-induced leakage of gastrointestinal ammonia into the common bloodstream in rats

  2011cites this paper
• Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins.

  2011cites this paper
• 사람 폐암 세포주에서 시스플라틴이나 독소루비신의 세포독성에 미치는 녹차 추출물의 영향

  2011cites this paper
• Quality of life in ovarian cancer.

  2011cites this paper
• The role of Hoxa7 and Pax8 in epithelial ovarian cancer differentiation

  2010cites this paper
• articleA genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

  2010cites this paper
• Ammonia redistribution from the gastrointestinal tract to general circulation after intraperitoneal injection of cyclophosphamide to rats

  2010cites this paper
• Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer

  2010cites this paper
• Health-related quality of life assessments assist in defi ning optimal management of ovarian cancer . Quality of Life in Ovarian Cancer

  2010cites this paper
• Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines.

  2010cites this paper
• The financial impact of genetic information on the insurance industry

  2010cites this paper
• Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression

  2010cites this paper
• A Case of Bowel Perforation in a Patient with Advanced Recurrent Ovarian Cancer Treated with the Molecular Targeted Agent Bevacizumab

  2010cites this paper
• Continuing Therapy beyond Adjuvant Chemotherapy to Optimise Cure in Advanced Ovarian Cancer: a Dream Coming True?

  2010cites this paper
• Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006

  2010cites this paper
• Maligner Aszites

  2009cites this paper
• Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

  2009cites this paper
• Intravital fiber-optic fluorescence imaging for monitoring ovarian carcinoma progression and treatment response

  2009cites this paper
• Chemotherapy for Early-stage High-risk Endometrial Cancer

  2009cites this paper
• Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.

  2009cites this paper
• Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

  2009cites this paper
• Maligne Ovarialtumoren in der Schwangerschaft

  2009cites this paper
• Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.

  2008cites this paper
• ERCC5 is a novel biomarker of ovarian cancer prognosis.

  2008cites this paper
• Clinical Outcome and Prognostic Factors in Borderline Ovarian Tumors and Invasive Ovarian Carcinomas in Western Sweden

  2008cites this paper
• Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer

  2008cites this paper
• Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.

  2008cites this paper
• Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models

  2008cites this paper
• Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.

  2008cites this paper
• Massive anterior chest wall metastasis of ovarian cancer and prolonged survival after treatment: a case report.

  2008cites this paper
• Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.

  2007cites this paper
• Maternal–fetal transport kinetics of carboplatin in the perfused human placental lobule: In vitro study

  2007cites this paper
• Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer.

  2007cites this paper
• Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer

  2007cites this paper
• Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.

  2007cites this paper
• Operative Treatment of Ovarian Cancer and Borderline Tumors in Different Hospital Categories in Finland

  2007cites this paper
• Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.

  2006cites this paper
• Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment

  2006cites this paper